Live tape
Top 8, mentions 7d14,356NVDA4,865 mentions▲ +0.04GOOGL2,063 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,108 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

KROS

NASDAQ

Keros Therapeutics (KROS)

10.63 USD +0.28% vs prior close
Keros Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
208.6M USD
Revenue, year to Dec 2025
244.1M USD
EPS, diluted, year to Dec 2025
2.30 USD
52-week range
10 USD – 22 USD
Avg volume
65.1K

as of Jul 17, 2026

Have Keros Therapeutics (KROS) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Keros Therapeutics insiders reported 4 open-market sales and 1 purchase (SEC Form 4).

Form 4, 90 days to 10 Nov 2026, newest reported trade 18 Aug 2026

1buys
4sells
$91Knet sold
0other filings
Have Keros Therapeutics (KROS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
18 Aug 2026Cho EstherChief Legal OfficerSell4,48546K USD
18 Aug 2026Newton Charles W.DirectorSell5516K USD
18 Aug 2026Lerner Lorena RaquelChief Scientific OfficerSell3,56837K USD
18 Aug 2026Tanini AnnitaCorp. Controller & VP, FinanceSell1,22413K USD
17 Aug 2026BIENAIME JEAN JACQUESDirectorBuy1,00010K USD
Bought1 open-market purchase1,000$10K
Sold4 open-market sales9,828$101K

Which funds hold Keros Therapeutics (KROS)?

9 of the 45 institutional funds we track reported a Keros Therapeutics position for the quarter ended 30 Jun 2026 — a combined 28.1M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Keros Therapeutics (KROS)?
FundPositionSharesValueShares q/q
AQR Capital ManagementAdded967,85910.4M USD+138.1%
Citadel AdvisorsHeld (±25%)396,0984.2M USD−2.6%
Renaissance TechnologiesHeld (±25%)359,0863.8M USD−20.8%
D. E. Shaw & Co.Trimmed267,4602.9M USD−47.5%
Two Sigma InvestmentsTrimmed246,6492.6M USD−32.2%
Millennium ManagementAdded184,8222.0M USD+73.0%
Man GroupTrimmed155,5411.7M USD−34.8%
Marshall WaceNew position34,600370K USD
Point72 Asset ManagementTrimmed10,393111K USD−90.5%
Tudor Investment CorpExited

What has been filed or recorded for Keros Therapeutics (KROS)?

The filings we hold for Keros Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Keros Therapeutics (KROS)?
And
09 Oct 2026Fails to deliverShares failed to deliver7 shares81 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 0.70 USDRevenue $40M
30 Sep 2026FinancialsTotal assets307.4M USDat period end
30 Sep 2026FinancialsTotal equity279.1M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.45 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.21 USDRevenue $0M
31 Dec 2025Annual reportFY 2025 reportedEPS 2.30 USDRevenue $244M
31 Dec 2025FinancialsRevenue244.1M USDfiscal year
31 Dec 2025FinancialsNet income87.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS2.30 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.18 USDRevenue $14M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.76 USDRevenue $18M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 3.62 USDRevenue $211M
31 Dec 2024Annual reportFY 2024 reportedEPS −5.00 USD

What do people ask about Keros Therapeutics (KROS)?

From live data
What is Keros Therapeutics’ market cap?208.6M

Keros Therapeutics is worth 208.6M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Keros Therapeutics’ revenue?244.1M

Keros Therapeutics reported revenue of 244.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Keros Therapeutics insiders bought or sold shares recently?4 sales

In the 90 days to 10 Nov 2026, Keros Therapeutics insiders reported 4 open-market sales and 1 purchase (SEC Form 4). See Insiders

Which funds own Keros Therapeutics?9 of 45

9 of the 45 funds we track reported a Keros Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Citadel Advisors and Renaissance Technologies. See Funds

When did Keros Therapeutics last report earnings?0.70

Keros Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.70 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings